Phase I/II Study of KRN330 plus Irinotecan After First-Line or Adjuvant FOLFOX [5-fluorouracil, leucovorin and oxaliplatin]/CapOx Failure in Patients with Metastatic Colorectal Cancer.

Trial Profile

Phase I/II Study of KRN330 plus Irinotecan After First-Line or Adjuvant FOLFOX [5-fluorouracil, leucovorin and oxaliplatin]/CapOx Failure in Patients with Metastatic Colorectal Cancer.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 25 Mar 2015

At a glance

  • Drugs KRN 330 (Primary) ; Irinotecan
  • Indications Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Kyowa Hakko Kirin
  • Most Recent Events

    • 01 Oct 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 29 Aug 2012 Planned end date changed from 1 Aug 2012 to 1 Oct 2012 as reported by ClinicalTrials.gov.
    • 09 Jan 2012 Planned end date changed from 1 Jun 2012 to 1 Aug 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top